The following is an excerpt of an op-ed published by Pour Demain in Tech Policy Press . The article provides nuance to the innovation vs...

Current geopolitical tensions and rapid technological developments have necessitated an urgent reassessment of biological risks and their...

Medical diagnostics, biomanufacturing, and many other parts of the bioeconomy rely on synthetic nucleic acids (NAs). Clinicians and...

As the European Union prepares to implement the AI Act, ensuring robust evaluation methods for General Purpose AI (GPAI) models is...

Biotech: Ensure safety to maximise progress. Safeguards needed for responsible innovation.

In an era where General Purpose AI (GPAI) models are becoming increasingly prevalent and powerful, the need for robust incident reporting...

With a return-on-investment of CHF 290 for every CHF 1 spent during an ordinary winter, savings orders of magnitudes higher during a...

En mai 2024, le Conseil de l'Europe a adopté le premier traité international contraignant au monde sur l'intelligence artificielle (IA)....

Avec le début de la mise en œuvre du AI Act de l'UE, un mécanisme crucial pour l'application des réglementations sur les modèles d'IA à...

Pour Demain outlines the foundations of a risk management framework upon a request by the OECD.